Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS

August 17, 2026 6:50 AM
UBS analyst Ashwani Verma raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $49.00 (from $45.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change